• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Adare Pharma Solutions

    Syngene

    Quotient Sciences

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Aphena Pharma Solutions

    Syngene

    Alcami

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Alcami Sells Netherlands Site to MerachemSyncom

    Expands portfolio of chemistry services from compound design to clinical proof of concept.

    Related CONTENT
    • Alcami
    • Trial Runners
    • SGS Life Sciences
    • Parexel Adds Experts to Regulatory Consulting Group
    • Merck to Acquire ArQule for $2.7B
    01.09.20
    MercachemSyncom, a mid-sized European drug-discovery contract research organization (CRO), has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands. The acquisition will allow MercachemSyncom to support larger scale clinical active pharmaceutical ingredient (API) requirements, alongside current capabilities in Prague, as well as bringing state-of-the-art solid-state research capabilities. The long experience of the Weert team in designing and driving early clinical drug substance development programs will complement extensive process research capabilities based in Groningen and Nijmegen. Financial terms were not disclosed.
     
    “Since the merger of Mercachem and Syncom in 2017, our activities in early drug substance development have grown significantly,” said Frank Leemhuis, managing director, MercachemSyncom. “However, it is a real challenge to find experienced development chemists—both analytical and synthetic. With the addition of the Alcami Weert team, we have the perfect technical and cultural match. With modern, flexible plant capacity, we look forward to supporting many more clinical development programs for our customers.”
     
    The Weert facility, originally founded in 1999 as Chemshop B.V., has steadily developed into a state-of-the-art contract development and manufacturing organization (CDMO), with a highly skilled workforce focused on applying appropriate development to transition laboratory-scale chemistry to cGMP clinical drug substance production in an integrated, risk-managed fashion. The site employs reactors with capacities from 10L to 1000L and has delivered hundreds of clinical compounds since its inception. A recent addition includes a world-class high-throughput X-ray powder diffraction (XRPD) workflow to expand impressive physicochemical research capabilities, such as polymorph screening and salt selection studies, combined with crystallization process development on scale.
     
    Eelco Ebbers, chief executive officer, MercachemSyncom, said, “This acquisition, in combination with our existing activities in drug discovery, gives us the opportunity to expand our portfolio of chemistry services from compound design to clinical proof of concept and beyond, all located within the European Union. We are extremely happy to acquire these operations, particularly as they come with such an experienced team. This is our second acquisition in the cGMP space, following our Prague site, and we already have a very healthy pipeline of opportunities from our existing loyal client base. We are excited about the additional capacity and capability we will be able to offer, particularly to our U.S. clients, where our business is growing rapidly. The Weert site has a proven track record and state-of-the-art facilities with a clean inspection history, including a recent FDA inspection.”
    Related Searches
    • chief executive officer
    • discovery
    • Development
    • production
    Suggested For You
    Alcami Alcami
    Trial Runners Trial Runners
    SGS Life Sciences SGS Life Sciences
    Parexel Adds Experts to Regulatory Consulting Group Parexel Adds Experts to Regulatory Consulting Group
    Merck to Acquire ArQule for $2.7B Merck to Acquire ArQule for $2.7B
    SK Bio Gains FDA Approval for XCOPRI SK Bio Gains FDA Approval for XCOPRI
    Biopharma Over 20 Years Biopharma Over 20 Years
    C2 Pharma Expands API Portfolio C2 Pharma Expands API Portfolio
    Grand River Grand River's Tom Ross
    Barentz Acquires Majority Share in IMCoPharma Barentz Acquires Majority Share in IMCoPharma
    Contract Pharma’s 20th Anniversary Series: CDMO Insight Contract Pharma’s 20th Anniversary Series: CDMO Insight
    Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future
    Vetio Animal Health Vetio Animal Health
    MilliporeSigma to Use Acoustic Technology for Cell Therapy Manufacturing MilliporeSigma to Use Acoustic Technology for Cell Therapy Manufacturing
    Contract Pharma’s 20th Anniversary Retrospective Contract Pharma’s 20th Anniversary Retrospective

    Related Breaking News

    • Breaking News | Drug Development | Industry News
      Bristol Myers Squibb Expands at Cambridge Crossing

      Bristol Myers Squibb Expands at Cambridge Crossing

      Adds remaining 113,000 square feet to its initial lease at 250 Water Street.
      Kristin Brooks 04.16.21

    • Breaking News | Drug Development | Industry News
       Amgen Completes Five Prime Acquisition

      Amgen Completes Five Prime Acquisition

      Gains pipeline of immuno-oncology and targeted cancer therapies, including a Phase 3 trial-ready, first-in-class program for gastric cancer.
      Kristin Brooks 04.16.21

    • Breaking News | Drug Development | Industry News
      BioVersys Gets EIB Funds to Address Antimicrobial Resistance

      BioVersys Gets EIB Funds to Address Antimicrobial Resistance

      Financing supports development of BioVersys’ breakthrough hospital antibiotic therapy targeting Acinetobacter baumannii
      Kristin Brooks 04.14.21


    • Breaking News | Clinical Trials | Drug Development | Trials & Filings
      FDA Accepts Airway Therapeutics’ IND for COVID Treatment

      FDA Accepts Airway Therapeutics’ IND for COVID Treatment

      To initiate a Phase 1b trial to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.
      Kristin Brooks 04.12.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Sanofi Acquires Tidal Therapeutics

      Sanofi Acquires Tidal Therapeutics

      Gains novel mRNA-based technology with research capabilities in immuno-oncology and inflammatory diseases, with potential in other disease areas.
      Kristin Brooks 04.12.21

    • Analytical Services | Breaking News | Clinical Trial Materials | Drug Development | Industry News
      Ascendia Pharmaceuticals Poised for Expansion

      Ascendia Pharmaceuticals Poised for Expansion

      CDMO secures growth equity investment from Signet Healthcare Partners.
      Tim Wright, Editor, Contract Pharma 04.09.21


    • Breaking News | Collaborations & Alliances | Drug Delivery | Drug Development | Industry News
      Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

      Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

      Work together to develop and commercialize CHI’s novel dry-powder inhaler product.
      Charles Sternberg, Assistant Editor 04.07.21

    • Breaking News | Clinical Trials | Drug Development | Industry News
      Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

      Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

      To support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.
      Kristin Brooks 04.06.21

    • Breaking News | Clinical Trials | CRO News | Drug Development
      Moleculin Selects IQVIA Biotech to Advance COVID Treatment

      Moleculin Selects IQVIA Biotech to Advance COVID Treatment

      IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
      Kristin Brooks 04.06.21


    • Breaking News | Drug Development
      Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

      Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

      Expands its oncology leadership capabilities in the U.S.
      Charles Sternberg, Assistant Editor 04.01.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined company brings complementary Ribosomal RNA-targeted genetic therapy platforms together.
      Kristin Brooks 04.01.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.
      Kristin Brooks 03.30.21


    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Facilities | Industry News
      Chime Biologics Expands CDMO Capabilities

      Chime Biologics Expands CDMO Capabilities

      Completes $190 million financing round to accelerate capacity expansion.
      Tim Wright, Editor, Contract Pharma 03.29.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development | Industry News
      CyanVac and Exothera Enter COVID-19 Vaccine Partnership

      CyanVac and Exothera Enter COVID-19 Vaccine Partnership

      CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.
      Tim Wright, Editor, Contract Pharma 03.25.21

    • Breaking News | Drug Development | Facilities | Industry News | Parenterals
      Eisai Begins Construction of New Injection/Research Building

      Eisai Begins Construction of New Injection/Research Building

      To accommodate expanded drug discovery targets and new modalities such as antibodies, ADCs, and nucleic acid drugs.
      Kristin Brooks 03.22.21

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Ensuring Pharma Manufacturing Quality
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Executive Moves: Novavax
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login